financetom
Business
financetom
/
Business
/
Why 3D Systems Stock Is Climbing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why 3D Systems Stock Is Climbing
Jun 4, 2024 2:32 PM

3D Systems Corporation ( DDD ) shares are trading higher Tuesday after the company received a multi-year purchase agreement with an estimated value of around $250 million through 2028. 

The Details

3D Systems ( DDD ) announced the signing of a multi-year purchase agreement, with a value estimated to approach a quarter-billion dollars, in support of the indirect manufacturing process for clear aligners. 

The company also announced its expanded focus and technology roadmap tailored to deliver a range of solutions for a growing digital dentistry market. The portfolio will include solutions for alignment, protection, repair and replacement of teeth. 

3D Systems ( DDD ) targeted the commercial launch of direct printing technology for clear aligners targeted for late 2025. 

Related News: What’s Going On With Greenwave Technology Stock?

DDD Stock Prediction 2024

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

Shares of 3D Systems ( DDD ) have an average 1-year price target of $8.25, representing an expected upside of 138.44%.

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on 3D Systems ( DDD ), while one analyst has a bullish rating: Cantor Fitzgerald has the shares as Overweight and a price target of $8.25.

DDD Price Action: According to Benzinga Pro, 3D Systems ( DDD ) shares are up 17.05% after-hours at $4.05 at the time of publication Tuesday.

Read Next: CrowdStrike Q1 Earnings: Revenue Beat, EPS Beat, Raised Guidance On Positive Momentum, ‘Exceptional Strength’

This illustration was generated using artificial intelligence via Dall-E

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Freedom Holding to Establish New Brokerage Firm in Turkey
Freedom Holding to Establish New Brokerage Firm in Turkey
Jan 14, 2025
04:26 AM EST, 01/14/2025 (MT Newswires) -- Freedom Holding ( FRHC ) said Tuesday it is launching a new brokerage firm in Turkey. The Capital Markets Board of Turkey has decided to grant a license to the company's Freedom Financial Services subsidiary to establish the new brokerage company, Freedom Yatirim Menkul Degerler JSC. The company said it expects to allocate...
Hutchmed Says Orpathys Receives Full Approval in China
Hutchmed Says Orpathys Receives Full Approval in China
Jan 14, 2025
04:20 AM EST, 01/14/2025 (MT Newswires) -- Hutchmed ( HCM ) said late Monday that China's National Medical Products Administration has approved its supplemental new drug application for Orpathys to treat certain adult patients with non-small cell lung cancer. The drugmaker said the regulator also converted Orpathys' prior conditional approval for previously treated patients to full approval. The updated label...
Merit Medical Systems Poised to Report Revenue Growth in 2024; Shares Jump Premarket
Merit Medical Systems Poised to Report Revenue Growth in 2024; Shares Jump Premarket
Jan 14, 2025
04:23 AM EST, 01/14/2025 (MT Newswires) -- Merit Medical Systems ( MMSI ) said late Monday it expects revenue of about $1.355 billion to $1.357 billion for the year ended Dec. 31, a projected increase of about 7.7% to 7.9% from a year earlier. Analysts polled by FactSet expect $1.348 billion. Shares of the company rose more than 7% in...
Vaxart Says Oral Covid-19 Vaccine Candidate Recommended for Continued Study
Vaxart Says Oral Covid-19 Vaccine Candidate Recommended for Continued Study
Jan 14, 2025
04:09 AM EST, 01/14/2025 (MT Newswires) -- Vaxart ( VXRT ) said late Monday an independent data safety monitoring board has recommended that a phase 2b trial of its oral Covid-19 vaccine candidate continue without any modifications. The company said the US Food and Drug Administration is reviewing the safety data from the study. Upon favorable review, the company will...
Copyright 2023-2026 - www.financetom.com All Rights Reserved